Vivitonin 100 mg Tablets

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Propentofylline

Available from:

MSD Animal Health UK Limited

ATC code:

QC04AD90

INN (International Name):

Propentofylline

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Cardio Vascular

Authorization status:

Authorized

Authorization date:

1994-09-30

Summary of Product characteristics

Revised: April 2021
AN: 02063/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vivitonin 100mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Propentofylline
100.00mg/tablet
Film coating ingredients:
Yellow ferric oxide (E172) (colouring)
0.258mg/tablet
Titanium Dioxide (E171) (colouring)
0.856mg/tablet
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Ochre, biconvex, oblong filmcoated tablets.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For
improvement
in
dullness,
lethargy
and
overall
demeanour
in
dogs.
Vivitonin is particularly useful in older dogs, where it may increase
willingness
to exercise and exercise tolerance.
4.3
CONTRA-INDICATIONS
Not to be administered to pregnant bitches or breeding animals.
Do not use in animals with known hypersensitivity to the active
substance or
any of the excipients
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
None
Revised: April 2021
AN: 02063/2020
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Specific diseases (e.g. kidney disease) should be treated accordingly.
In the case of renal failure, the dose should be reduced.
Consideration should be given to rationalising the medication of dogs
already receiving treatment for congestive heart failure or bronchial
disease.
ii.
Special
precautions
to
be
taken
by
the
person
administering
the
medicinal product to the animals
Care should be taken to avoid accidental ingestion.
Wash hands after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Vomiting has been observed on rare occasions, particularly at the
commencement of therapy.
In rare cases allergic reactions (e.g. urticaria) may occur and these
necessitate discontinuation of the treatment.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals displaying adverse
reaction(s)
during the course of one treatment)
- common (more than